| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Panobinostat |
| Brand | Farydak® |
| Indication | In combination with bortezomib and dexamethasone, for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent. |
| Assessment Process | |
| Rapid review commissioned | 26/01/2016 |
| Rapid review completed | 09/02/2016 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended |
Not considered cost-effective due to non-submission of full pharmacoeonomic evaluation
